311 related articles for article (PubMed ID: 19526289)
1. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
2. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
4. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
[TBL] [Abstract][Full Text] [Related]
6. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
Silva C; Fuxe K; Chadi G
J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
Burks S; Raymick J; Robinson B; Hanig J; Sarkar S
Neurosci Lett; 2019 Jun; 703():86-95. PubMed ID: 30890473
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.
Sarkar S; Chigurupati S; Raymick J; Mann D; Bowyer JF; Schmitt T; Beger RD; Hanig JP; Schmued LC; Paule MG
Neurotoxicology; 2014 Sep; 44():250-62. PubMed ID: 25064079
[TBL] [Abstract][Full Text] [Related]
10. Neurovascular changes in acute, sub-acute and chronic mouse models of Parkinson's disease.
Sarkar S; Raymick J; Mann D; Bowyer JF; Hanig JP; Schmued LC; Paule MG; Chigurupati S
Curr Neurovasc Res; 2014 Feb; 11(1):48-61. PubMed ID: 24274908
[TBL] [Abstract][Full Text] [Related]
11. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
12. Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease.
Tassan Mazzocco M; Serra M; Maspero M; Coliva A; Presotto L; Casu MA; Morelli M; Moresco RM; Belloli S; Pinna A
Exp Neurol; 2024 Apr; 374():114704. PubMed ID: 38281587
[TBL] [Abstract][Full Text] [Related]
13. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
14. ERK/MAP Kinase Activation is Evident in Activated Microglia of the Striatum and Substantia Nigra in an Acute and Chronically-Induced Mouse Model of Parkinson's Disease.
Sarkar S; Lu E; Raymick J; Hanig J; Gu Q
Curr Neurovasc Res; 2018; 15(4):336-344. PubMed ID: 30468126
[TBL] [Abstract][Full Text] [Related]
15. MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice.
Costa G; Frau L; Wardas J; Pinna A; Plumitallo A; Morelli M
Mov Disord; 2013 Dec; 28(14):1957-65. PubMed ID: 24108425
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
Elgueta D; Aymerich MS; Contreras F; Montoya A; Celorrio M; Rojo-Bustamante E; Riquelme E; González H; Vásquez M; Franco R; Pacheco R
Neuropharmacology; 2017 Feb; 113(Pt A):110-123. PubMed ID: 27693549
[TBL] [Abstract][Full Text] [Related]
18. The MPTP/probenecid model of progressive Parkinson's disease.
Carta AR; Carboni E; Spiga S
Methods Mol Biol; 2013; 964():295-308. PubMed ID: 23296790
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.
Carta AR; Kachroo A; Schintu N; Xu K; Schwarzschild MA; Wardas J; Morelli M
J Neurochem; 2009 Dec; 111(6):1478-89. PubMed ID: 19817968
[TBL] [Abstract][Full Text] [Related]
20. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
